Cargando…

Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update

In the last two years, the world encountered the SARS-CoV-2 virus, which is still dominating the population due to the absence of a viable treatment. To eradicate the global pandemic, scientists, doctors, and researchers took an exceptionally significant initiative towards the development of effecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharya, Manojit, Chatterjee, Srijan, Lee, Sang-Soo, Chakraborty, Chiranjib
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797221/ https://www.ncbi.nlm.nih.gov/pubmed/36586649 http://dx.doi.org/10.1016/j.ijbiomac.2022.12.284

Ejemplares similares

Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Can artificial intelligence-strengthened ChatGPT or other large language models transform nucleic acid research?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity
por: Bhattacharya, Manojit, et al.
Publicado: (2021)

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Structural Landscape of nsp Coding Genomic Regions of SARS-CoV-2-ssRNA Genome: A Structural Genomics Approach Toward Identification of Druggable Genome, Ligand-Binding Pockets, and Structure-Based Druggability
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Integrative Bioinformatics Approaches Indicate a Particular Pattern of Some SARS-CoV-2 and Non-SARS-CoV-2 Proteins
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

ChatGPT and large language models in orthopedics: from education and surgery to research
por: Chatterjee, Srijan, et al.
Publicado: (2023)

The D614G mutation helps to increase the transmissibility and reduce the virulence of SARS-CoV-2 variants through natural selection
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Designing, characterization, and immune stimulation of a novel multi-epitopic peptide-based potential vaccine candidate against monkeypox virus through screening its whole genome encoded proteins: An immunoinformatics approach
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Immunoinformatics Approach for the Identification and Characterization of T Cell and B Cell Epitopes towards the Peptide-Based Vaccine against SARS-CoV-2
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Understanding Gene Expression and Transcriptome Profiling of COVID-19: An Initiative Towards the Mapping of Protective Immunity Genes Against SARS-CoV-2 Infection
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

A Next-Generation Vaccine Candidate Using Alternative Epitopes to Protect against Wuhan and All Significant Mutant Variants of SARS-CoV-2: An Immunoinformatics Approach
por: Bhattacharya, Manojit, et al.
Publicado: (2021)

Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Bioactivity, Molecular Mechanism, and Targeted Delivery of Flavonoids for Bone Loss
por: Sharma, Ashish Ranjan, et al.
Publicado: (2023)

Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

The current landscape of long COVID clinical trials: NIH’s RECOVER to Stanford Medicine’s STOP-PASC initiative
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Evaluation of differentially expressed genes during replication using gene expression landscape of monkeypox-infected MK2 cells: A bioinformatics and systems biology approach to understanding the genomic pattern of viral replication
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

A novel mutation-proof, next-generation vaccine to fight against upcoming SARS-CoV-2 variants and subvariants, designed through AI enabled approaches and tools, along with the machine learning based immune simulation: A vaccine breakthrough
por: Bhattacharya, Manojit, et al.
Publicado: (2023)

D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin?
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

The current second wave and COVID-19 vaccination status in India
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex
por: Bhattacharya, Manojit, et al.
Publicado: (2020)

Artificial intelligence enabled ChatGPT and large language models in drug target discovery, drug discovery, and development
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

SARS-CoV-2 and other human coronaviruses: Mapping of protease recognition sites, antigenic variation of spike protein and their grouping through molecular phylogenetics
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19
por: Saha, Abinit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4a2d2vi6ioidkjnd0sc1bi0e9n